For many pharmaceutical companies, LC-MS is the technique of choice to provide HCP identification and quantification data for industry regulators.
A data-rich LC-MS approach is ideal for facilitating in-process development decisions and for downstream HCP monitoring. Moreover, a single LC-MS workflow can be applied to multiple sample types expressed from any cell line.
Therefore, Covance has developed a pragmatic approach for routine HCP analysis by 1D LC-MS, to enable safer and faster drug development.
During this webinar, we will present evaluation of two workflows:
Using in-process samples associated with an antibody biosimilar development program, we demonstrate removal of identified HCPs at various stages of the product purification process, with potential to facilitate subsequent targeted absolute quantification._1594575463273